A highly efficient, low-toxic, wide-spectrum antibacterial coating designed for 3D printed implants with tailorable release properties

2017 ◽  
Vol 5 (22) ◽  
pp. 4128-4136 ◽  
Author(s):  
Chaowen Xue ◽  
Xiangwei Song ◽  
Mingzhuo Liu ◽  
Fanrong Ai ◽  
Miaoxing Liu ◽  
...  

A broad spectrum antibacterial coatings with tailorable release properties were developed for 3D printed implants.

Author(s):  
Xin Huang ◽  
Weizhao Zhao ◽  
Yuchen Liang ◽  
Minghui Wang ◽  
Yaling Zhan ◽  
...  

A simple and practical intermolecular Pummerer reaction using difluoroenol silyl ethers as nucleophiles is described. The protocol allows for highly efficient α-difluoroalkylation of a wide spectrum of alkyl sulfoxides.


ACS Photonics ◽  
2019 ◽  
Vol 7 (1) ◽  
pp. 88-97 ◽  
Author(s):  
Asa Asadollahbaik ◽  
Simon Thiele ◽  
Ksenia Weber ◽  
Aashutosh Kumar ◽  
Johannes Drozella ◽  
...  

2020 ◽  
Vol 8 (7) ◽  
pp. 1371-1382 ◽  
Author(s):  
Yunjian Yu ◽  
Lin Mei ◽  
Yanmei Shi ◽  
Xinge Zhang ◽  
Kesong Cheng ◽  
...  

A broad-spectrum antibacterial system was produced in which silver nanoparticle-conjugated graphene quantum dots were utilised as a blue light-enhanced nanotherapeutic for efficient ternary-mode antimicrobial therapy.


2019 ◽  
Vol 11 (38) ◽  
pp. 35510-35510
Author(s):  
J. Justin Koh ◽  
Gwendolyn J.H. Lim ◽  
Xin Zhou ◽  
Xiwen Zhang ◽  
Jun Ding ◽  
...  

2019 ◽  
Vol 11 (14) ◽  
pp. 13787-13795 ◽  
Author(s):  
J. Justin Koh ◽  
Gwendolyn J.H. Lim ◽  
Xin Zhou ◽  
Xiwen Zhang ◽  
Jun Ding ◽  
...  

2019 ◽  
Vol Volume 14 ◽  
pp. 5977-5987 ◽  
Author(s):  
Yanglong Zhu ◽  
Kuan Liu ◽  
Jianjian Deng ◽  
Jing Ye ◽  
Fanrong Ai ◽  
...  

2019 ◽  
Vol 29 (06) ◽  
pp. 733-743 ◽  
Author(s):  
Mari Nieves Velasco Forte ◽  
Tarique Hussain ◽  
Arno Roest ◽  
Gorka Gomez ◽  
Monique Jongbloed ◽  
...  

AbstractAdvances in biomedical engineering have led to three-dimensional (3D)-printed models being used for a broad range of different applications. Teaching medical personnel, communicating with patients and relatives, planning complex heart surgery, or designing new techniques for repair of CHD via cardiac catheterisation are now options available using patient-specific 3D-printed models. The management of CHD can be challenging owing to the wide spectrum of morphological conditions and the differences between patients. Direct visualisation and manipulation of the patients’ individual anatomy has opened new horizons in personalised treatment, providing the possibility of performing the whole procedure in vitro beforehand, thus anticipating complications and possible outcomes. In this review, we discuss the workflow to implement 3D printing in clinical practice, the imaging modalities used for anatomical segmentation, the applications of this emerging technique in patients with structural heart disease, and its limitations and future directions.


2020 ◽  
Vol 36 (4) ◽  
pp. 74-79
Author(s):  
Т.В. Bukharova ◽  
A.A. Buianova ◽  
K.S. Davygora ◽  
D.V. Goldshtein

Multipotent mesenchymal stromal cells (MSCs) can be used as a model for the development of gene and cell technologies and as a means of delivering nucleic acids to the body, including as part of tissue-engineering constructs. Small interfering RNA (siRNA) molecules acting by the RNA interference mechanism are a high-precision tool for genetic silencing of target mRNA transcripts. The search for low toxic and highly efficient transfection agents for delivery of siRNA or other nucleic acids to MSCs is an urgent task for the development of therapy based on these molecules. A comparative evaluation of five transfection agents showed that compounds based on cationic polymers were more efficient in delivering siRNA molecules than liposomes, while the cytotoxicity of all tested reagents was independent of their chemical structure. For two of the three transfection agents selected according to their efficiency and belonging to different classes, TurboFect and Lipofectamine® 3000, a moderate effect on cell viability was revealed. The results obtained allow us to recommend TurboFect and Lipofectamine® 3000 as highly efficient and relatively low-toxic agents for transfection of MSCs cultures. multipotent mesenchymal stromal cells, siRNA, transfection, lipofection, cationic lipids, cationic polymers, polyethyleneimine. The authors are grateful to staff of functional genomics laboratory of Research Centre for Medical Genetics Skoblova M.Yu. and Krivosheeva I.A., for technical and methodological assistance. The work was financially supported by the Ministry of Science and Higher Education of the Russian Federation within the state assignment for Research Centre for Medical Genetics.


2019 ◽  
Vol 8 (5) ◽  
pp. 199-206 ◽  
Author(s):  
C. L. Romanò ◽  
H. Tsuchiya ◽  
I. Morelli ◽  
A. G. Battaglia ◽  
L. Drago

Implant-related infection is one of the leading reasons for failure in orthopaedics and trauma, and results in high social and economic costs. Various antibacterial coating technologies have proven to be safe and effective both in preclinical and clinical studies, with post-surgical implant-related infections reduced by 90% in some cases, depending on the type of coating and experimental setup used. Economic assessment may enable the cost-to-benefit profile of any given antibacterial coating to be defined, based on the expected infection rate with and without the coating, the cost of the infection management, and the cost of the coating. After reviewing the latest evidence on the available antibacterial coatings, we quantified the impact caused by delaying their large-scale application. Considering only joint arthroplasties, our calculations indicated that for an antibacterial coating, with a final user’s cost price of €600 and able to reduce post-surgical infection by 80%, each year of delay to its large-scale application would cause an estimated 35 200 new cases of post-surgical infection in Europe, equating to additional hospital costs of approximately €440 million per year. An adequate reimbursement policy for antibacterial coatings may benefit patients, healthcare systems, and related research, as could faster and more affordable regulatory pathways for the technologies still in the pipeline. This could significantly reduce the social and economic burden of implant-related infections in orthopaedics and trauma.Cite this article: C. L. Romanò, H. Tsuchiya, I. Morelli, A. G. Battaglia, L. Drago. Antibacterial coating of implants: are we missing something? Bone Joint Res 2019;8:199–206. DOI: 10.1302/2046-3758.85.BJR-2018-0316.


Sign in / Sign up

Export Citation Format

Share Document